- Home
- CRBG vs GMAB Comparison
CRBG vs GMAB Comparison
Compare CRBG & GMAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CRBG
- GMAB
- Stock Information
- Founded
- CRBG 1957
- GMAB 1999
- Country
- CRBG United States
- GMAB Denmark
- Employees
- CRBG N/A
- GMAB N/A
- Industry
- CRBG Life Insurance
- GMAB Biotechnology: Pharmaceutical Preparations
- Sector
- CRBG Finance
- GMAB Health Care
- Exchange
- CRBG Nasdaq
- GMAB Nasdaq
- Market Cap
- CRBG 15.6B
- GMAB 17.4B
- IPO Year
- CRBG 2022
- GMAB N/A
- Fundamental
- Price
- CRBG $29.96
- GMAB $30.40
- Analyst Decision
- CRBG Buy
- GMAB Strong Buy
- Analyst Count
- CRBG 13
- GMAB 6
- Target Price
- CRBG $39.08
- GMAB $40.40
- AVG Volume (30 Days)
- CRBG 4.9M
- GMAB 2.6M
- Earning Date
- CRBG 11-03-2025
- GMAB 11-06-2025
- Dividend Yield
- CRBG 3.20%
- GMAB N/A
- EPS Growth
- CRBG N/A
- GMAB 132.41
- EPS
- CRBG 1.78
- GMAB 25.10
- Revenue
- CRBG $18,335,000,000.00
- GMAB $3,845,670,022.00
- Revenue This Year
- CRBG $0.38
- GMAB $24.92
- Revenue Next Year
- CRBG $5.43
- GMAB $15.97
- P/E Ratio
- CRBG $16.87
- GMAB $1.21
- Revenue Growth
- CRBG 15.16
- GMAB 29.57
- 52 Week Low
- CRBG $23.69
- GMAB $17.24
- 52 Week High
- CRBG $36.57
- GMAB $33.65
- Technical
- Relative Strength Index (RSI)
- CRBG 37.50
- GMAB 57.24
- Support Level
- CRBG $29.36
- GMAB $28.08
- Resistance Level
- CRBG $30.35
- GMAB $29.35
- Average True Range (ATR)
- CRBG 0.87
- GMAB 0.69
- MACD
- CRBG -0.16
- GMAB -0.07
- Stochastic Oscillator
- CRBG 18.60
- GMAB 98.73
About CRBG Corebridge Financial Inc.
Corebridge Financial Inc provides retirement solutions and insurance products in the United States. It offers a broad set of products and services through five segments Individual Retirement, Group Retirement, Life Insurance, Institutional Markets businesses, Corporate and Other. The majority of its revenue derives from the Individual Retirement segment.
About GMAB Genmab A/S ADS
Genmab is a Copenhagen-based biotechnology company specializing in antibody therapeutics for the treatment of cancer. Genmab's proprietary antibody technologies are DuoBody, HexaBody, DuoHexaBody, and HexElect. Johnson & Johnson partnered with Genmab to create Darzalex, which is regarded as the standard of care for multiple myeloma and is Genmab's leading product. Genmab also has Tepezza for thyroid eye disease (partnered with Horizon), Kesimpta for relapsing multiple sclerosis (partnered with Novartis), Rybrevant (partnered with Johnson & Johnson) for non-small cell lung cancer (NSCLC), Tivdak (partnered with Seagen) for cervical cancer, and Epkinly (partnered with AbbVie) for diffuse large B-cell lymphoma. Genmab has several pipeline candidates targeting other oncologic indications.